Search clinical trials for: iodine I 131 monoclonal antibody A33

Total 288 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Duke University

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

Brain and Central Nervous System Tumors | Metastatic Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Sarcoma | Lung Cancer | Brain and Central Nervous System Tumors | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
Duke University

Completed

Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
University of Nebraska
National Cancer Institute (NCI); Coulter Pharmaceutical, Inc.

Terminated

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Colorectal Cancer

United States, Australia
Peregrine Pharmaceuticals

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Brain and Central Nervous System Tumors

United States
Duke University
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors

Brain and Central Nervous System Tumors

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Kidney Cancer

United States
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Thyroid Cancer

United States
John Maris

Available

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Neuroblastoma | Childhood Metastatic Pheochromocytoma

United States
GlaxoSmithKline

Completed

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Colorectal Cancer | Metastatic Cancer

United States
Corixa Corporation

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Non-Hodgkin's Lymphoma

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Non-Hodgkin's Lymphoma

United States
University of Michigan Rogel Cancer Center
GlaxoSmithKline

Active, not recruiting

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...

Completed

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
GlaxoSmithKline

Completed

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Non-Hodgkin's Lymphoma

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Completed

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Lymphoma, Non-Hodgkin
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United Kingdom, United States
GlaxoSmithKline

Completed

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Memorial Sloan Kettering Cancer Center

Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Metastatic Cancer | Neuroblastoma | Intraocular Melanoma | Melanoma (Skin) | Retinoblastoma

United States
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission | Adult Acute Lymphoblastic Leukemia in Remission | Refractory Anemia With Excess Blasts | Refractory... and other conditions

United States
Darell D. Bigner, MD, PhD
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Brain and Central Nervous System Tumors | Neuroblastoma

United States
Garden State Cancer Center at the Center for Molecular...

Unknown

Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

Colorectal Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer

Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the Liver

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | Lymphoid Leukemia in Remission

United States

Search clinical trials for: iodine I 131 monoclonal antibody A33

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations